title: Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma.
abstract: OBJECTIVE
  Induction high-dose chemotherapy followed by myeloablative melphalan (HD-Mel) treatment and autologous hematopoietic stem-cell support (autoSCT) is a standard treatment for multiple myeloma (MM) either upfront or in relapse after conventional treatment. We performed a retrospective analysis of consecutive patients undergoing a late repeat HD-Mel/autoSCT treatment for MM.
  
  
  METHODS
  Data from 24 consecutive patients with MM who underwent a myeloablative treatment with HD-Mel late after completion of upfront first high-dose therapy were assessed for toxicity, response, progression-free survival (PFS) and time to next treatment (TTNT). These data were correlated with the results obtained after the initial high dose therapy and autoSCT.
  
  
  RESULTS
  A total of 23 patients were treated with novel drugs (lenalidomide, thalidomide, bortezomib) after relapse to initial autoSCT. The median overall survival (OS) of all patients was 90 months. 19 patients (79%) achieved a very good partial remission (VGPR) or complete remission (CR) after initial autoSCT, compared with 42% after late autoSCT. PFS and TTNT were 19 and 24 months after initial compared with 13 and 21 months after late autoSCT. Univariate analysis identified initial response duration and the achievement of a CR/VGPR after the initial transplantation to be associated with prolonged response after repeat autoSCT.
  
  
  CONCLUSIONS
  Our data indicate that late high-dose treatment followed by autoSCT is safe and effective after upfront intensive treatment, can bridge to allogeneic SCT, and encourage collection of an additional graft.
authors.forename: Helge
authors.initials: H
authors.lastname: Menzel
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Hinmüller
authors.forename: Hans-Jochem
authors.initials: HJ
authors.lastname: Kolb
authors.forename: Tibor
authors.initials: T
authors.lastname: Schuster
authors.forename: Alexander
authors.initials: A
authors.lastname: Hoellein
authors.forename: Christian
authors.initials: C
authors.lastname: Peschel
authors.forename: Tobias
authors.initials: T
authors.lastname: Dechow
authors.forename: Ulrich
authors.initials: U
authors.lastname: Keller
keywords: high-dose therapy; multiple myeloma; stem-cell transplantation
references.citation: Bone Marrow Transplant. 2009 Mar;43(5):417-22
references.pmid: 18850013
references.citation: Haematologica. 2006 Jan;91(1):141-2
references.pmid: 16434386
references.citation: N Engl J Med. 2007 Nov 22;357(21):2123-32
references.pmid: 18032762
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: Am J Hematol. 2006 Jun;81(6):426-31
references.pmid: 16680735
references.citation: Blood. 2011 Mar 17;117(11):3025-31
references.pmid: 21228328
references.citation: N Engl J Med. 2009 Jun 18;360(25):2645-54
references.pmid: 19535803
references.citation: Curr Opin Hematol. 2010 Nov;17(6):538-43
references.pmid: 20827188
references.citation: N Engl J Med. 2007 Mar 15;356(11):1110-20
references.pmid: 17360989
references.citation: Semin Hematol. 2003 Oct;40(4 Suppl 4):8-16
references.pmid: 15015891
references.citation: N Engl J Med. 2011 Mar 17;364(11):1046-60
references.pmid: 21410373
references.citation: Blood. 2011 Aug 18;118(7):1979-88
references.pmid: 21690560
references.citation: Oncology. 2003;65 Suppl 2:94-8
references.pmid: 14586157
references.citation: Blood. 2009 Apr 30;113(18):4137-43
references.pmid: 19182205
references.citation: Bone Marrow Transplant. 2008 Sep;42(6):413-20
references.pmid: 18587435
references.citation: Eur J Haematol. 2005 Nov;75(5):391-5
references.pmid: 16191088
references.citation: Cancer. 2006 Mar 1;106(5):1084-9
references.pmid: 16456814
references.citation: N Engl J Med. 2003 Dec 25;349(26):2495-502
references.pmid: 14695409
references.citation: Br J Haematol. 2007 Aug;138(3):330-7
references.pmid: 17614819
references.citation: Blood. 2005 Jun 1;105(11):4532-9
references.pmid: 15731182
references.citation: Leukemia. 2006 Sep;20(9):1467-73
references.pmid: 16855634
references.citation: Cancer Treat Rev. 2011 Jun;37(4):266-83
references.pmid: 20863623
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3892-901
references.pmid: 17679727
references.citation: N Engl J Med. 2003 May 8;348(19):1875-83
references.pmid: 12736280